Details of the Drug Reposition

General Information of This Drug (ID: DMLRBXM)

Drug Name	Q-301 DMLRBXM

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hepatitis C virus infection	DISQ0M8R	1E51.1	Phase 2	[1]
Atopic dermatitis	DISTCP41	EA80	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02426359) Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)